09 August 2021 | News
Partnership licenses GlymaxX technology to enable fine-tuning of the fucose content of the antibody
Photo Credit: depositphotos
ProBioGen and ValenzaBio jointly initiate a cell line development project involving the application of ProBioGen's proprietary GlymaxX technology.
ValenzaBio's VB119 is a clinical-stage antibody for which ProBioGen will generate a new CHO-based expression system. Besides the CHO.RiGHT® cell line development platform, ProBioGen will apply its ADCC modulating GlymaxX technology. GlymaxX enables fine-tuning of the fucose content of the antibody towards the originator molecule's fucose content. The GlymaxX technology is easy to use and its flexibility in terms of fucosylation adjustment enables its application for innovative molecules as well as for biosimilar projects.
ProBioGen's Chief Scientific Officer Volker Sandig said, "Being entrusted with such a project underlines the value of our cell line development expertise and technologies we have developed in the past decades."
Tatyana Touzova, Chief Operating Officer at ValenzaBio, added: "The conversion to a new expression system could help ensure VB119 reaches its full potential for patients. ProBioGen possesses a unique set of experiences and technologies using their GlymaxX platform. We are privileged to partner with such an impressive group of scientists and advance a program that we believe can be an important new therapy for patients."